CDC Narrows RSV Vaccine Guidelines Due to Safety Concerns
The U.S. Centers for Disease Control and Prevention (CDC) has recently narrowed its original recommendations for the respiratory syncytial virus (RSV) vaccine, citing concerns over the risk of a side effect that can lead to paralysis or death. The recommendations originally stated adults over the age of 60 should receive the vaccine, but updates in […]
Guillain-Barré Syndrome ‘More Common Than Expected’ in Early RSV Vaccine Trial
Reports of the nervous system disorder Guillain-Barré syndrome (GBS) were “more common than expected” in the older adult population who received the new vaccine for respiratory syncytial virus (RSV). The data, reported by the U.S. Centers for Disease Control and Prevention (CDC), matched trial data reported earlier this year.1 GBS is a “polio-like” inflammatory autoimmune […]
CDC Pushes Pfizer’s Pentavalent Meningococcal Vaccine
On Oct. 20, 2023, Pfizer, Inc. announced that the U.S. Food and Drug Administration (FDA) approved its new pentavalent meningococcal vaccine, Penbraya, which targets five meningococcal serogroups (A, B, C, W and Y) that most commonly cause meningococcal disease in adolescents and young adults 10-25 years old. Penbraya, is recommended to be given in two […]
RSV Vaccines for Senior Adults Linked to Guillain-Barré Syndrome
On Feb. 29, 2024, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) presented a preliminary analysis that showed that 23 adults over the age of 65 who received a respiratory syncytial virus (RSV) vaccine developed Guillain-Barré syndrome (GBS).1 When a person develops GBS, including after an infection or […]
Some Children Suffered Seizures Following mRNA COVID Shots
A 2023 analysis published by researchers from Kaiser Permanente and the U.S. Centers for Disease Control and Prevention (CDC) in the journal Pediatrics compared vaccine adverse outcomes following administration of Pfizer/BioNTech’s Comirnaty messenger RNA (mRNA) COVID-19 shot and Moderna/NIAID’s Spikevax mRNA COVID-19 shot among recipients under five years old for a period of 1-21 days […]
Guillain-Barré Syndrome Linked to the RSV Vaccine
The potential risk of Guillain-Barré syndrome (GBS) developing after receipt of Pfizer’s respiratory experimental syncytial virus (RSV) vaccine have prompted the U.S. Food and Drug Administration (FDA) to request that Pfizer conduct a post-marketing safety study if the vaccine is approved for use in the United States this spring.1 The RSV vaccine manufactured by GlaxoSmithKline […]
